Sign In
Buy HROW
$33.32
+0.460 (+1.40%)
At Close: Jun 03, 2026
Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients
07:00am, Thursday, 10'th Apr 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All (“VAFA”) pro
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
04:30pm, Saturday, 29'th Mar 2025
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbur
Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call
02:00pm, Friday, 28'th Mar 2025
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Ca
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
01:39pm, Friday, 28'th Mar 2025
Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and impro
Harrow (HROW) Q4 Earnings and Revenues Top Estimates
07:45pm, Thursday, 27'th Mar 2025
Harrow (HROW) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.27 per share a year ago.
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
04:01pm, Thursday, 27'th Mar 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024.
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
10:45am, Thursday, 27'th Mar 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financia
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
04:01pm, Monday, 17'th Mar 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quar
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
08:50am, Saturday, 01'st Mar 2025
Harrow Health's robust distribution platform and patented eye care products create a strong moat, offering an attractive entry point after the recent stock price correction. Catalysts in 2025 could co
I Am Loading Up Big Dividends For My Golden Years
07:35am, Monday, 17'th Feb 2025
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesse
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a stra
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
07:00am, Tuesday, 07'th Jan 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chi
Those Derisked Baby Bonds Of Harrow, Inc.
03:43pm, Friday, 03'rd Jan 2025
Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product s
Harrow: The Triesence Relaunch
12:09am, Saturday, 14'th Dec 2024
Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Tr
